Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Recently approved for cardiovascular disease management by the FDA in March 2024, Wegovy is the first weight loss medication to offer this dual benefit
Work with a qualified healthcare provider to establish safe caloric targets, monitor for nutrient deficiencies, and adjust other medications as needed
1 Introduction The gutbrain peptide, glucagon-like peptide-1 (GLP-1), is encoded by the proglucagon (PPG) gene, which is expressed in the intestines and pancreas [for a review, see PPG gene is also expressed in the olfactory bulb ( The extensive physiological and behavioral effects of GLP-1 are mediated by the GLP-1 receptors (GLP-1R), which are expressed in both the central and autonomic nervous systems ( Following ingestion of a meal, the GLP-1 levels rapidly increase
Health officials and clinicians increasingly consider GLP-1 drugs to be a major advancement in treating obesity, a condition that disproportionately affects older adults and contributes to a range of costly and debilitating illnesses
We want to stress the importance of weight loss as a medical therapy that can help: lower blood pressure control blood sugar relieve pain in arthritic joints improve the course of scores of medical conditions Are you ready to schedule an appointment
The benefits of GLP-1 RAs go beyond just lowering blood sugar
